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The objective of this meta-analysis is to assess the impact of LH supplementation in women undergoing in vitro
fertilization/ intracytoplasmic sperm injection (IVF/ICSI) with gonadotropin releasing hormone (GnRH) antagonist
protocol. No significant difference in outcomes between LH supplementation and r-FSH alone in women
undergoing IVF/ICSI with GnRH antagonist protocol is currently present, and further studies are necessary for
more solid conclusions on pregnancy likelihood to be drawn.
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Compared to GnRH agonists which dominate in the area
of assisted reproductive technology(ART) accounting for
its essential role in circumventing the problem of a pre-
mature luteinizing hormone (LH) surge since the mid-
1980s, GnRH antagonists generate a prompt suppression
of gonadotrophin release, but do not cause the flare-up
effect, by specifically blocking the GnRH receptors and
ultimately induce a decrease in serum LH levels and a
less pronounced decrease in FSH secretion [1]. However,
it is unpredictable whether or not GnRH antagonists
cause a decline in serum oestradiol during follicular re-
cruitment which would result in an adverse effect on the
pregnancy outcome [2]. On the other hand, GnRH an-
tagonists tend to oversuppress endogenous LH if the
dosage or timing of use was not appropriately controlled.
As it is reported that endogenous low level of LH influ-
ences detrimentally both on the development of normal
healthy follicles, because growing follicles become in-
creasingly sensitive to and finally dependent on LH for* Correspondence: syp2008@vip.sina.com
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unless otherwise stated.their development [3], and on the endometrium after
ovulation because sufficient LH is indispensable for the
resumption of meiosis and for the production of proges-
terone. Therefore, it seems urgent for clinical doctors to
add exogenous LH while GnRH antagonist protocol is
applied to pituitary down-regulation in case of adverse
effect on the pregnancy outcomes.
Nevertheless, there still has been no ultimate conclusion
about the effect of r-LH supplementation to r-FSH in GnRH
antagonist protocol on the pregnancy outcomes according
to the recent studies. The issue on LH supplementation in
women undergoing IVF/ICSI with GnRH antagonist for
pituitary down-regulation has caused a heated debate
around the world [4]. The studies by Sauer et al. (2004),
Griesinger et al. (2005), Levi-Setti et al. (2006) did not dem-
onstrate any beneficial effect of LH supplementation on the
oocytes quality and the pregnancy outcomes [5-7], while
two randomized trials have shown higher pregnancy rates
among those receiving rLH with GnRH agonist protocol
[8,9]. It is noticeable that the meta-analysis published in
2007 and 2010 separately showed no advantage in combin-
ation of r-LH with r-FSH in women undergoing IVF/ICSI
with GnRH antagonist protocol compared with r-FSH alonetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow chart of the study selection process used for a
systematic review and meta-analysis, undertaken to investigate the
effect of recombinant human luteinizing hormone supplementation
in women undergoing IVF/ICSI with antagonist protocol.
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warrants further research [12].
A recent systemic review and meta-analysis concluded
that the combination of r-hLH with r-FSH stimulation en-
hanced the clinical pregnancy and implantation rates in pa-
tients aged ≥35 [13]. Similar results were reported in an
open-label randomized controlled study by Bosch et al.
(2011) which found that r-LH is beneficial in improving the
implantation rate in women aged 36–39 years [14], although
König et al. (2013) argued that the pretreatment with hor-
monal contraceptives before stimulation and the LH supple-
mentation on stimulation day 1, while in his randomized
controlled trial LH supplementation was given on stimula-
tion day 6, might play an essential role in the discrepancy
between two studies [15]. Until now, there has been no
meta-analysis to review whether the LH supplementation
benefits the advanced reproductive aged patients undergoing
IVF/ICSI with GnRH antagonist protocol.
GnRH antagonist protocol depends on the occurrence of
spontaneous menses, which is different from long GnRH
agonist protocol in which ovarian stimulation can be
initiated after pituitary desensitization has been achieved
[16,17]. Therefore, pretreatment with oral contraceptive pill
(OCP) before stimulation was applied in order to prevent
ovarian cysts, for the sake of synchronous follicular devel-
opment and predictingtiming events in an IVF/ ICSI cycle
regarding scheduling [18]. In the studies by Sauer et al.
(2004), Levi-Setti et al. (2006), Bosch et al. (2011), the pa-
tients were pretreated with OCP and used the GnRH an-
tagonist protocol for COH, but no special benefits was
shown in r-LF + r-FSH group compared with the r-FSH
only group [6,7,14]. Consequently, it is necessary to explore
whether combination of r-LH with r-FSH for COH benefits
the pregnancy outcomes in women undergoing IVF or
ICSI-ET with GnRH antagonist protocol and oral contra-
ceptive pills pretreatment by meta-analysis.
Based on the above considerations, the present meta-
analysis was performed to answer the questions: (1) whether
combination of r-LH with r-FSH for COH benefits the preg-
nancy outcomes in general women undergoing IVF/ICSI
with GnRH antagonist protocol;(2) whether combination of
r-LH with r-FSH for COH benefits the pregnancy outcomes
in advanced reproductive aged women undergoing IVF/ICSI
with GnRH antagonist protocol; (3) whether combination of
r-LH with r-FSH for COH benefits the pregnancy outcomes
in women undergoing IVF/ICSI with GnRH antagonist
protocol and pretreated with oral contraceptive pills.
Methods
Systematic search and strategy
A systemic search of the relevant literature was performed
without language limitation but restricted to randomized
controlled trials (RCTs). We mainly explored MEDLINE,
EMBASE, Web of science and Cochrane Library for therelevant studies about the effect of combination of r-LH
with r-FSH for COH in patients undergoing IVF/ICSI with
GnRH-antagonist protocol on IVF/ICSI outcomes. The fol-
lowing search strategy was used: ("luteinizing hormone" or
"recombinant luteinizing hormone" or "lh" or "r-LH" or "hlh"
or "recombinant lh" or "ovarian stimulation" or "recombin-
ant FSH" or "lutropin alfa" or "recombinat human LH")
AND ( "GnRH antagonist") AND (“assisted reproductive
techniques” or “ART” or “IVF”or “ICSI” or “in vitro fertiliza-
tion”or “intracytoplasmic sperm injections”) AND (“ran-
domized controlled trial ” or “clinical trial” or “multicenter
study” or “controlled study” or “double blind procedure” or
“single blind procedure”).
Inclusion and exclusion criteria
Inclusion criteria were RCTs that compared the effect of re-
combinant follicle-stimulating hormone (r-FSH) alone and
combination with recombinant luteinizing hormone (r-LH)
in women undergoing IVF/ICSI with GnRH antagonist
protocol on IVF/ICSI outcomes. Exclusion criteria included
failure to report appropriate randomization procedures,
participants as poor responders, or outcomes unclear or
inappropriate.
Data extraction
Studies were screened by two reviewers (Y.X. and Z.B.)
independently and any disagreement was solved unani-
mously by discussion. Firstly, all titles and abstracts from
the databases were examined, but only those with the
possibility of meeting the predefined criteria were kept
for further evaluation. Secondly, final inclusion deci-
sions were made on examination of the full manu-
scripts. If the published study was judged to contain
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Figure 2 Forest plot of ongoing pregnancy per ET with or without r-LH supplementation for COH in general population undergoing
IVF or ICSI-ET with GnRH antagonist protocol.
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The following data were recorded from each of the
studies: methodologic (randomization method)was de-
clared, number of patients included (rLH + rFSH/rFSH),
inclusion criteria, ovarian stimulation protocol, Gn type
and initial dosage (IU/d), Gn type and initial dosage
(IU/d), rLH protocol, use of oral contraceptive pretreat-
ment with and primary outcomes in each article.
Outcome parameters
The main outcome measure chosen for the current
meta-analysis was ongoing pregnancy per ET (defined as
the presence of fetal heart activity on ultrasound at
12 weeks of gestation per ET) and clinical pregnancy per
ET. The primary adverse effect was OHSS. Secondary
outcome measures included days of stimulation, amount
of r-FSH dose used, number of retrieved oocytes per oo-
cyte retrieval, number of mature oocytes (metaphase II)
per oocyte retrieval, fertilization rate, implantation rate,
serum oestrodial on hCG day (pg/ml), serum progester-
one on hCG day (ng/ml).
Quantitative analysis
All results were combined for meta-analysis with Revman
Software (Version 5, The Cochrane Collaboration, 2003).
Continuous variables were expressed as weighted mean dif-
ference (WMD) with 95% confidence intervals (CIs). Di-
chotomous data for each unit of analysis were expressed as
an odds ratio (OR) with 95% CIs. Heterogeneity was evalu-
ated using the Q-test and I2-index values, and reported for
each outcome as a P-value and percentage, respectively. Bias
was assessed at the study level using a qualitative reviewFigure 3 Forest plot of clinical pregnancy per ET with or without r-LH
or ICSI-ET with GnRH antagonist protocol.assessing randomization, double blinding, and withdrawals
and dropouts. In the absence of statistical heterogeneity a
summary estimate of the odds ratio with a 95% was calcu-
lated in a fixed-effect model using the Peto modification of
the Mantel- Haenszel method. In case of significant statis-
tical heterogeneity, we performed sensitivity analysis using
the random-effect model. A P-value <0.05 was considered
statistically significant.Results
Systematic review
The search strategy retrieved a total of 532 references, 29
full text articles were reviewed, and from these 5 trials met
full inclusion criteria [5-7,14,15] and were included in the
analysis with no disagreement noted between the reviewers
responsible for study selection (Figure 1). Further details
about these studies are provided in the Table 1. All the five
trials were meta-analyzed to compare r-FSH combined with
r-LH versus r-FSH alone in GnRH antagonist protocols in
the general population. Two trials were meta-analyzed to
compare r-FSH combined with r-LH versus r-FSH alone in
GnRH antagonist protocols in advanced reproductive aged
women [14,15]. In addition, three trials were meta-analyzed
to compare r-FSH combined with r-LH versus r-FSH alone
in GnRH antagonist protocols in patients pretreated with
oral contraceptive pills [6,7,14].Meta-analysis
Combination of r -LH with r -FSH versus r -FSH alone for
COH in general population undergoing IVF or ICSI-ET
with GnRH antagonist protocol.supplementation for COH in general population undergoing IVF
Figure 4 Forest plot of incidence of OHSS with or without r-LH supplementation for COH in general population undergoing IVF or
ICSI-ET with GnRH antagonist protocol.
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Ongoing pregnancy per ET
Three trials with a total of 365 embryo transfers pro-
vided data on the ongoing pregnancy per ET [5,7,15].
The pooled analysis with these three trials did not show
differences between the r-LH supplementation group
and the r-FSH alone group (three trials: OR 0.80; 95% CI
0.49 to 1.31) and there was no indication of statistical
heterogeneity (Figure 2).
Clinical pregnancy per ET
Two trials with a total of 271 embryo transfers provided
data on the clinical pregnancy per ET [6,15]. The pooled
analysis with these three trials did not show differences
between the r-LH supplementation group and the r-FSH
alone group (two trials: OR 0.90; 95% CI 0.65 to 1.42)
and there was no indication of statistical heterogeneity
(Figure 3).
Incidence of ovarian hyperstimulation syndrome (OHSS)
There was no evidence of a statistical difference in inci-
dence of OHSS (five trials: OR 1.14, 95% CI 0.45 to 2.91)
and there was no indication of statistical heterogeneity
(Figure 4).
Secondary outcomes
Four trials reported on serum progesterone level on
hCG day [5,7,14,15]. Pooling the data resulted in a sig-
nificantly higher serum oestradiol level (WMD 237.39,
95% CI 134.58 to 340.20) (Figure 5) and lower serum
progesterone level (WMD −0.16, 95% CI −0.22 to −0.10)Figure 5 Forest plot of serum oestrodial level on hCG day with or withou
IVF or ICSI-ET with GnRH antagonist protocol.in the r-LH supplementation group than in the r-FSH
alone group (Figure 6).
The data from the trials was pooled separately and
there was no evidence of a statistical difference in r-FSH
total dose used per treatment cycle regarding r-FSH total
dose used per treatment cycle (four trials: WMD −77.96,
95% CI −211.46 to 55.53), total days of stimulation per
treatment cycle (four trials: WMD 0.20, 95% CI −0.37 to
0.76), number of retrieved oocytes per oocyte retrieval
(four trials: WMD 0.58, 95% CI −1.27 to 0.1), number of
mature oocytes (metaphase II) per oocyte retrieved(two
trials: OR 0.88; 95% CI 0.66 to 1.17), fertilization rate
(two trials: OR1.03; 95% CI 0.89 to 1.20) and implant-
ation rate (three trials: OR 0.76; 95% CI 1.51 to 1.13).
Combination of r-LH with r-FSH versus r-FSH alone
for COH in advanced reproductive aged women under-
going IVF or ICSI-ET with GnRH antagonist protocol r-
FSH total dose used per treatment cycle.
r-FSH total dose used per treatment cycle
Two trials reported data on r-FSH dose used per treat-
ment cycle [5,14]. There was a statistical difference in r-
FSH total dose used per treatment cycle (two trials:
WMD −89.86, 95% CI −96.59 to −83.13) (Figure 7).
Serum oestrodial level on hCG day
Two trials reported on serum oestradiol level on hCG
day [14,15]. Pooling the data resulted in a significantly
higher serum oestradiol level in the r-LH supplementa-
tion group than in the r-FSH alone group (WMD
245.46, 95% CI 104.85 to 386.06) (Figure 8).t r-LH supplementation for COH in general population undergoing
Figure 6 Forest plot of serum progesterone level on hCG day with or without r-LH supplementation for COH in general population
undergoing IVF or ICSI-ET with GnRH antagonist protocol.
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Both of the two trials reported on the number of retrieved
oocytes per oocyte retrieval [14,15]. Pooling the data
showed a significantly higher number of retrieved oocytes
per oocyte retrieval in the r-FSH alone group (two trials:
WMD −1.3, 95% CI −2.29 to −0.32) (Figure 9).
Other outcomes
Pooling the data in the trials did not show a significant dif-
ference between the r-LH supplementation group and the
r-FSH alone group regarding the total days of stimulation
per treatment cycle (two trials: WMD −0.05, 95% CI −0.73
to 0.64), incidence of OHSS (three trials: OR 1.77, 95% CI
0.38 to 8.32), serum progesterone level on hCG day
(WMD −0.04, 95% CI −0.46 to −0.38).
Combination of r-LH with r-FSH versus r-FSH alone
for COH in women undergoing IVF or ICSI-ET with
GnRH antagonist protocol and oral contraceptive pills
pretreatment.
Total days of stimulation per treatment cycle
Two trials reported on the total days of stimulation per
treatment cycle [6,14]. Pooling the data showed a signifi-
cantly higher total days of stimulation per treatment
cycle in the r-LH supplementation group than in the r-
FSH alone group (two trials: WMD 0.49, 95% CI 0.12 to
0.85) and there was no indication of statistical hetero-
geneity (Figure 10).
Serum progesterone level on hCG day
Two trials reported on serum oestradiol and progester-
one level on hCG day [7,14]. Pooling the data resulted in
a significantly higher serum progesterone level in the r-
FSH alone group than in the r-LH supplementation
group (WMD −0.19, 95% CI −0.25 to −0.13) (Figure 11).Figure 7 Forest plot of rFSH total dose used per treatment cycle with o
aged women undergoing IVF or ICSI-ET with GnRH antagonist protocolOther outcomes
No evidence of a significant difference was found between
the r-LH supplementation group and the r-FSH alone
group regarding incidence of ovarian hyperstimulation syn-
drome (OHSS) (three trials: OR 0.84, 95% CI 0.25 to 2.78) ,
r-FSH total dose used per treatment cycle (two trials:
WMD −211.90, 95% CI −319.99 to −103.82), serum oestro-
dial level on hCG day (WMD 321.71, 95% CI −117.44 to
760.86), number of retrieved oocytes per oocyte retrieval
(two trials: WMD −0.69, 95% CI −1.52 to 0.13), r-FSH total
dose used per treatment cycle (two trials: WMD −211.90,
95% CI −319.99 to −103.82).
Discussion
Our systematic review and meta-analysis addressed the
issue on the comparison of the outcomes between the
combination of r-LH with r-FSH and r-FSH alone for
COH in women undergoing IVF/ICSI with GnRH antag-
onist protocol and the comparisons in the subgroups of
advanced reproductive aged women and women pre-
treated with oral contraceptive pills were also carried out.
Based on the “two-cell, two-gonadotropin” theory, the LH
and FSH play a critical role in stimulating the two cellular
components of ovary, which are theca cell and granulosa
cell, leading to the production of ovarian steroids [19,20]. At
the earlier stage of follicular development, FSH is indispens-
able for follicular growth and the formation of estrogen by
inducing the aromatase enzyme converting androgen to es-
tradiol [21], while the androgen production from cholesterol
is dependent on the stimulation of the theca cells by LH
and FSH together [22]. Although FSH can induce follicular
growth even without LH, there was identified that the folli-
cles would have developmental deficiencies, following hCG
administration [23], which suggested that the effect of LH
on follicular development was probably not only due tor without r-LH supplementation for COH in advanced reproductive
.
Figure 8 Forest plot of serum oestrodial level on hCG day with or without r-LH supplementation for COH in advanced reproductive
aged women undergoing IVF or ICSI-ET with GnRH antagonist protocol.
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exerting a direct effect on the stimulation and modulation
of folliculogenesis [24]. It is noticeable that both the theca
cell and granulosa cell produce significant amount of pro-
gesterone, which was converted into androgens under the
influence of LH. Therefore, the LH supplementation re-
sulted in the lower serum progesterone level. As is well
established, increased exposure to progesterone can advance
the endometrium, leading to asynchrony of embryo devel-
opment to endometrial development and the reduction of
implantation. Under this context, the LH supplementation
may be beneficial for the serum oestradiol and progesterone
level on the day of HCG administration.
As is predicted, our results suggested a beneficial effect
of r-LH supplementation on ovarian stimulation in serum
oestradiol and progesterone level on the day of HCG ad-
ministration in general population. However, there was no
evidence of beneficial effect in ongoing pregnancy per ET;
clinical pregnancy per ET; incidence of OHSS; r-FSH total
dose used per treatment cycle; total days of stimulation
per treatment cycle; number of retrieved oocytes per oo-
cyte retrieval; number of mature oocytes (metaphase II)
per oocyte retrieval; fertilization rate; implantation rate,
which was in accordance with the result of the meta-
analysis by Monique H Mochtar et al. (2010) [3].
With regard to LH supplementation for the advanced re-
productive aged women undergoing IVF or ICSI with
GnRH antagonist protocol, different trials showed different
results. The study by Bosch et al. (2011) obtained aFigure 9 Forest plot of number of retrieved oocytes per oocyte retrie
reproductive aged women undergoing IVF or ICSI-ET with GnRH antasignificantly better implantation rate and a clinically better
ongoing pregnancy rate among those patients aged 36 to
39. However, the study by König et al. 2013 showed no
benefit of LH supplementation in controlled ovarian stimu-
lation for IVF/ICSI with GnRH antagonists on pregnancy
rates in patients of 35 years or older. Then we pooled the
data from the two trials, showing a significantly higher
serum oestradiol level and significantly lower r-FSH total
dose used per treatment cycle found in the combination
of r-LH with r-FSH compared to r-FSH alone for COH in
advanced reproductive aged women undergoing IVF/ICSI
with GnRH antagonist protocol. Although a significantly
lower number of retrieved oocytes per oocyte retrieval
was also found in the combination of r-LH with r-FSH
group and the data of ongoing pregnancy or clinical preg-
nancy per ET were not available, we can not make the
conclusion that LH supplementation was not beneficial
for advanced reproductive aged women, since according
to Bosch et al., the combination of r-LH with r-FSH group
showed similar metaphase II oocytes and a better
fertilization rate, thus suggesting that the oocytes obtained
were of better quality, which would, in turn, lead to a
higher implantation [14]. More trials and meta-analyses
are needed to explore the role of LH supplementation
played in advanced reproductive aged women.
Since oral contraceptive pills pretreatment is a con-
venient way for clinics to schedule oocyte retrievals, it
will be more often applied by US clinics, although it is
reported that oral contraceptive pills pretreatmentval with or without r-LH supplementation for COH in advanced
gonist protocol.
Figure 10 Forest plot of total days of stimulation per treatment cycle with or without r-LH supplementation for COH in women under-
going IVF or ICSI-ET with GnRH antagonist protocol and oral contraceptive pills pretreatment.
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by extending the duration of treatment and the amount of
FSH required to get to the same criteria of hCG [25], espe-
cially when stimulation is started immediately after OC
withdrawal. This meta-analysis was not designed to detect
a clinical relevant difference in ongoing pregnancy rate be-
tween pretreatment with or without oral contraceptive pills.
Our results suggest a good effect of r-LH supplementation
in ovarian stimulation in serum progesterone level on the
day of HCG administration (WMD −0.19, 95% CI −0.25
to −0.13). Significantly lower serum progesterone level was
observed in the combination of r-LH with r-FSH group
compared to r-FSH alone group for COH in women under-
going IVF or ICSI with GnRH antagonist protocol and oral
contraceptive pills pretreatment. This might be due to the
fact that oral contraceptive pills pretreatment could have
had an influence on the endocrine environment in the fol-
licular phase by means of endogenous gonadotropin con-
trol [26] and FSH acts on granulosa cells to facilitate the
conversion of cholesterol into P, which is transferred to the
thecal cells to be converted into androgens under the action
of LH, therefore LH supplementation lowered serum pro-
gesterone level [27]. Moreover, lower progesterone level,
subsequently, increased endometrium receptivity. Under
this context, LH supplementation may be the optimal op-
tion by increasing the beneficial effect of LH administration
in this particular population. Our results also show a sig-
nificantly higher total days of stimulation per treatment
cycle (WMD 0.49, 95% CI 0.12 to 0.85) while significantly
lower r-FSH total dose used per treatment cycle (WMD
−211.90, 95% CI −319.99 to −103.82).
However, it has to be acknowledged that there still are
some limitations in our meta-analysis. Firstly, the combinedFigure 11 Forest plot of serum progesterone level on hCG day with o
IVF or ICSI-ET with GnRH antagonist protocol and oral contraceptivesample size of the five studies is still too small to confiden-
tially detect a clinically relevant difference with regard to
pregnancy likelihood between the two treatment modalities,
especially when taking the subgroups into consideration,
only the data from two or three trials were available for
meta-analysis. Secondly, inclusion criteria of the selected
trials were not as strict as possible, meaning that the inclu-
sion criteria bias existed in the paper. For instance, when
analyzing the outcomes of combination of r-LH with r-FSH
comparing with r-FSH alone for COH in women undergo-
ing IVF or ICSI with GnRH antagonist protocol in general
population general population, all trials should be limited
into those in which all the patients were pretreated with
oral contraceptive pills or not, the initiation of LH supple-
mentation was on the same stimulation day, and also ended
on another same day, moreover, the initial dosage of FSH
and LH was kept accordance with each trials. The last but
not the least, the data of the trials was not all available for
the meta-analysis, although the author was contacted if ne-
cessary, which resulted into that less trials were analyzed in
the subgroup.
Conclusions
To conclude, the present meta-analysis found no statistically
significant differences in outcomes of pregnancy between
the combination of r-LH with r-FSH group and r-FSH alone
group for COH with GnRH antagonist protocol in general
population, in advanced reproductive aged women and in
women pretreated with oral contraceptive pills undergoing
IVF/ICSI. More studies are necessary for more solid conclu-
sions on pregnancy likelihood after combination of r-LH
with r-FSH for COH in GnRH antagonist protocol to be
drawn.r without r-LH supplementation for COH in women undergoing
pills pretreatment.
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